Alexandra Gerlach, Senior Content Producer

Quadruple therapies including immunotherapy agents show promise in treating patients with multiple myeloma.

Gender disparities among oncology health care professionals have significant consequences for both the physicians and the patients they treat.

Isatuximab is used in combination with bortezomib, lenalidomide, and dexamethanose.

UC Davis Health researchers uncover substantial treatment disparities and inequal access to autologous hematopoietic cell transplantation therapy among multiple myeloma patients.

Speakers at the 2024 Society of Pain and Palliative Care Virtual Conference discussed advanced treatment opportunities for patients with substance use disorder (SUD) and cancer-related pain.

Continued disparities of gender representation in cardiovascular research reveal oversights that impact adequate diagnosis and treatment of cardiovascular disease in women.

A lipoprotein (a) (Lp[a]) assay has been granted breakthrough device designation to expand identification of patients with elevated Lp(a) and genetic predispositions to cardiovascular disease.

Inavolisib was submitted to the FDA for review as a first-line treatment for advanced HR-positive, HER2-negative PIK3CA-mutated breast cancer.

Researchers from the University of Leipzig Medical Center identify multiple biomarkers associated with the success of CAR T cell therapy in relapsed multiple myeloma.

New research reveals the potential of community pharmacists in minor ailment treatment, allowing for diversified patient care during growing health care professional shortages.

Researchers from the University of Manchester have developed a technique using rotaxane actuators in force-controlled release systems, enabling precise and efficient release of multiple molecules simultaneously.

Ten harmful and potentially deadly side effects of commonly prescribed medications.